Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

5

XI.ba Nonrespiratory AE of interest

5
Last update : 21/04/2019
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Atezolizumab
2
Avelumab
1
CTLA4 blocking immunotherapy
3
Camrelizumab
1
Ipilimumab
4
Lambrolizumab
4
Nivolumab
5
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pedelizumab
1
Pembrolizumab
5
Tislelizumab
1
Tremelimumab
1
Vaccination - Immunization
2
Vaccines
3
Zimberelimab
1

Publications

Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases.
Melanoma research 2019 Oct;29;516-521 2019 Oct
Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: a case report.
Anti-cancer drugs 2019 Aug;30;e0764 2019 Aug
Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy.
Cardiology in review 2019;27;97-107 2019
Identifying and managing the adverse effects of immune checkpoint blockade.
Journal of thoracic disease 2018 Feb;10;S480-S489 2018 Feb

Powered by

  • ^
  • Contact
  • Cookies
  • About